Since the last week of October 2021, ECBD is fully accessible to the whole scientific community that can from now on take full advantage of all available public data. Currently, there is only one public assay from the EU-OS partner site at the Fraunhofer Institute, IME ScreeningPort, focusing on the SARS-CoV-2 cytopathic effect in Vero E6 EGFP cells. However, more public assays should pour into ECBD in a near future, together with other already uploaded data under an embargo being made public sooner or later.
The real data burst should arrive in the first half of 2022 with various assays measured as a part of the EU-OS bioprofiling activities. The bioprofiling of the whole EU-OS compound library will investigate various compound properties, including their cytotoxicity, solubility, or promiscuity within biological assays. This should ensure that resources are invested in genuine hit compounds, which directly and specifically affect the drug target. These public datasets will also represent a valuable resource for data scientists concerning their employment for machine learning tasks.